TAZOBACTAM

DRUG6 trials

Sponsors

Hellenic Institute For The Study Of Sepsis, Assistance Publique Hopitaux De Paris, Centre Hospitalier Universitaire De Rennes, Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca, Merck Sharp & Dohme LLC

Conditions

Bacterial PneumoniaInfectious diseasesOther Infectious DiseasesSevere infectionsantibiotic therapy in Sepsissepsis

Phase 2

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

CompletedNCT03485950

M.D. Anderson Cancer CenterOther Infectious Diseases

Start: 2018-05-16End: 2022-02-16Updated: 2022-03-15

Phase 3

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

CompletedNCT02493764

Merck Sharp & Dohme LLCBacterial Pneumonia

Start: 2015-11-24End: 2019-04-03Updated: 2020-04-16

A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS (The MODIFY trial)

Active, not recruitingCTIS2022-502962-26-00

Hellenic Institute For The Study Of SepsisSevere infections

Start: 2023-09-14Target: 190Updated: 2025-11-03

BICCS - Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis

Not yet recruitingCTIS2024-516849-39-01

Assistance Publique Hopitaux De Parisantibiotic therapy in Sepsis

Target: 600Updated: 2025-12-02

BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection

Not yet recruitingCTIS2025-522819-42-01

Centre Hospitalier Universitaire De Rennessepsis

Target: 672Updated: 2026-08-06

Phase 4

Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)

Not yet recruitingCTIS2025-524264-38-00

Fundacio Hospital Universitari Vall D’Hebron Institut De RecercaInfectious diseases

Target: 136Updated: 2026-05-05

Related Papers

Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.

2026-01-26

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

Open Forum Infectious Diseases2023-05-043 citations

A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies

Open Forum Infectious Diseases2022-02-1413 citations

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

Clinical and Translational Science2021-10-2730 citations

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Clinical Infectious Diseases2020-07-06211 citations